Skip to main content
BC Innovations
Feature Story

Raising the CohBar

CohBar and USC found a new mitochondrial peptide that could help treat diabetes

By Lauren Martz, Staff Writer

A recently discovered mitochondrial peptide with metabolic effects on skeletal muscle suggests mitochondrial DNA may deserve a second look as a source of therapeutic targets. A group from CohBar Inc. and the University of Southern California found the peptide encoded in the mitochondrial genome, showed it mimics the effect of exercise and believes it could help treat Type II diabetes.

It's far from clear how many therapeutic targets might be encoded in mitochondrial DNA, although that has been the basis of CohBar's platform since it was founded in 2007. In January, the company completed an IPO that brought in $11.25 million to help transfer the discoveries from USC into the company's labs.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.